Johnson & Johnson announced new results from the Phase 1b/2 OrigAMI-4 study evaluating the efficacy and safety of subcutaneous, SC, amivantamab ...

I watch too much TV. I stream way more than I want. I love to read, and as a writer, I could argue, I need to read more. But ...

Johnson & Johnson today announced promising new results from the Phase 1b/2 OrigAMI-4 study evaluating the efficacy and safety of subcutaneous (SC) amivantamab monotherapy in patients with human ...

Thieves in Washington have repeatedly stolen public bronze artworks in recent years, often selling the raw materials for a ...

From brands reinventing with mycelium to design collectives disrupting the industry with cost visibility: these homegrown ...

Sometimes when words are not enough, art finds a way to speak for us. For Aswathy Krishnakumar, a clinical psychologist and ...

In the shadowy corridors of global cyber espionage, a new and increasingly aggressive actor has emerged, one that is ...

Sometimes, a movie leaves us with a finale so head-scratching, so profoundly ambiguous, that the credits roll and all we can ...

If you eat bread heels without thinking twice, congratulations on your middle-class-or-above upbringing. If you save them in ...

New findings from this investigational study build on the strength of the data for amivantamab in non-small cell lung cancer and broadens its potential across additional solid tumours 1,2 “Patients ...

With his recent exhibition at Keyes Art Mile still on everyone’s lips, and new work showing at Latitudes Art Fair 2025, Sizwe ...